Through the Eastern Cooperative Oncology Group (ECOG), the American Oncologic Hospital (AOH) of the Fox Chase Cancer Center is attempting to improve both the quality and duration of cancer patients' lives by developing and scientifically evaluating the most effective treatment programs for all types and stages of cancer. The AOH has 3 principal objectives as related to the ECOG. 1. To increase the accrual rate of patients on ECOG protocols by fostering an AOH multidisciplinary commitment to the use of ECOG protocols and by encouraging staellite institutions to enter patients on appropriate studies. 2. To increase the quality of protocol patient evaluation by having a principal ECOG protocol coordinator supervise the activities of 2 medical, 1 surgical, and 1 radiation therapy protocol coordinators at AOH as well as supervise the data managers at the satellite institutions. 3. To contribute to the scientific effort of the ECOG by developing combined modality protocols utilizing chemotherapy, radiation therapy, and surgery, developing group-wide chemotherapy protocols, publishing results of ECOG studies, and participating in ECOG Committees.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA027525-08
Application #
3556874
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-06-01
Project End
1989-04-30
Budget Start
1986-05-01
Budget End
1987-04-30
Support Year
8
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Ritchie, Christine S; Zhao, Fengmin; Patel, Kanan et al. (2017) Association between patients' perception of the comorbidity burden and symptoms in outpatients with common solid tumors. Cancer 123:3835-3842
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519
Goldstein, Lori J; Zhao, Fengmin; Wang, Molin et al. (2017) A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group ( Breast Cancer Res Treat 165:375-382
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004
Diefenbach, Catherine S; Li, Hailun; Hong, Fangxin et al. (2015) Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171:530-8
Willis, Scooter; De, Pradip; Dey, Nandini et al. (2015) Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene 4:129-41
Moore, Halle C F; Unger, Joseph M; Phillips, Kelly-Anne et al. (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-32

Showing the most recent 10 out of 63 publications